Purging iron from the heart

British Journal of Haematology

Volumn 125, Issue 5, 2004, Pages 545-551

  Hershko, Chaim ^a,b   Cappellini, Maria D ^c   Galanello, Renzo ^d   Piga, Antonio ^e   Tognoni, Gianni ^f   Masera, Giuseppe ^g  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c Ospedale Policlinico Milano   (Italy)

^d Dept of Biomed Sci and Biotech ^*  (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f Consorzio Mario Negri Sud ^*  (Italy)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Deferiprone; Desferrioxamine; Haemosiderosis; Heart; Iron chelation

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; EVALUATION; HEART DISEASE; HEART MUSCLE BIOPSY; HEART PROTECTION; HEMOSIDEROSIS; HUMAN; MEDICAL DOCUMENTATION; MEDICAL INFORMATION; MYOCARDIAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; VALIDATION PROCESS;

CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MAGNETIC RESONANCE SPECTROSCOPY; PYRIDONES;

EID: 2942616383     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04946.x     Document Type: Review

References (48)

1. Al-Refaie, F.N., Sheppard, L.N., Nortey, P., Wonke, B. & Hoffbrand, A.V. (1995) Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. British Journal of Haematology, 89, 403-407.
2. Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Ward, S.E., Agnew, J.E. & Hilson, A.J. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica, 84, 113-117.
3. Anderson, L.J., Holden, S., Davis, B., Prescott, E., Charrier, C.C., Bunce, N.H., Firmin, D.N., Wonke, B., Poerter, J., Walker, J.M. & Pennell, D.J. (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. European Heart Journal, 22, 2171-2179.
4. Anderson, L.J., Wonke, B., Prescott, E., Holden, S., Walker, J.M. & Pennell, D.J. (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet, 360, 516-520.
5. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Piga, A., Di Gregorio, F., Gamberini, M.R., Sabato, V., Melevendi, C., Cappellini, M.D. & Verlato, G. (1998) Survival and disease complications in thalassemia major. Annals of New York Academy of Sciences, 850, 227-231.
6. Brittenham, G.M., Farrell, D.E., Harris, J.W., Feldman, E.S., Danish, E.H., Muir, W.A., Tripp, J.H. & Bellon, E.M. (1982) Magnetic-susceptibility measurement of human iron stores. New England Journal of Medicine, 307, 1671-1675.
7. Brittenham, G.M., Griffith, P.M., Nienhuis, A.W., McLaren, C.E., Young, N.S., Tucker, E.E., Allen, C.J., Farrell, D.E. & Harris, J.W. (1994) Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine, 331, 567-573.
8. Buja, L.M. & Roberts, W.C. (1971) Iron in the heart. Etiology and clinical significance. American Journal of Medicine, 51, 209-221.
9. Calleja, E.M., Shen, J.Y., Lesser, M., Grady, R.W., New, M.I. & Giardina, P.J. (1998) Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Annals of New York Academy of Sciences, 850, 469-470.
10. Ceci, A., Baiardi, P., Felisi, M., Cappellini, M.D., Carnelli, V., De Sanctis, V., Galanello, R., Maggio, A., Masera, G., Piga, A., Schettini, F., Stefano, I. & Tricta, F. (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 118, 330-336.
11. Cohen, A.R., Mizanin, J. & Schwartz, E. (1989) Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. Journal of Pediatrics, 115, 151-155.
12. Cohen, A.R., Martin, M. & Schwartz, E. (1990) Current treatment of Cooley's anemia. Intravenous chelation therapy. In: Sixth Cooley's Anemia Symposium, Annals of New York Academy of Sciences Vol. 612 (ed. by A. Bank), pp. 286-292.
13. Collins, A.F., Fassos, F.F., Stobie, S., Lewis, N., Shaw, D., Fry, M., Templeton, D.M., McClelland, R.A., Koren, G. & Olivieri, N.F. (1994) Iron-balance and dose-response studies of the oral irn chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood, 83, 2329-2333.
14. Davis, B.A. & Porter, J.B. (2000) Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood, 95, 1229-1236.
15. Decker, M.D. & Edwards, K.M. (1988) Central venous catheter infections. Pediatric Clinics of North America, 35, 579-612.
16. Finch, C.A., Deubelbeiss, K., Cook, J.D., Eschbach, J.W., Harker, L.A., Funk, D.D., Marsaglia, G., Hillman, R.S., Slichter, S., Adamson, J.W., Ganzoni, A. & Giblett, E.R. (1970) Ferrokinetics in man. Medicine (Baltimore), 49, 17-53.
17. Gabutti, V. & Borgna-Pignatti, C. (1994) Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's Clinical Haematology, 7, 919-940.
18. Giardina, P.J., Grady, R.W., Ehlers, K.H., Burstein, S., Graziano, J.H., Markenson, A.L. & Hilgartner, M.W. (1990) Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine. In: Sixth Cooley's Anemia Symposium, Annals of New York Academy of Sciences Vol. 612 (ed. by A. Bank), pp. 275-285.
19. Gomori, J.M., Horev, G., Tamary, H., Zandback, J., Kornreich, L., Zaizov, R., Freud, E., Krief, O., Ben-Meir, J. & Rotem, H. (1991) Hepatic iron overload: quantitative MR imaging. Radiology, 179, 367-369.
20. Grady, R.W., Berdoukas, V., Rachmilewitz, E.A., Galanello, R., Borgna-Pignatti, C., Ladis, V., Sitarou, M., Hadjigavriel, M. & Giardina, P. (2002) Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. Blood, 100, 241a.
21. Hershko, C. & Weatherall, D.J. (1988) Iron-chelating therapy. Critical Reviews in Clinical and Laboratory Sciences, 26, 303-345.
22. Hershko, C., Link, G., Pinson, A., Peter, H.H., Dobbin, P. & Hider, R.C. (1991) Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood, 77, 2049-2053.
23. Hoffbrand, A.V. & Wonke, B. (1989) Results of long-term subcutaneous desferrioxamine therapy. Bailliere's Clinical Haematology, 2, 345-359.
24. Hoffbrand, A.V., Al-Refaie, F., Davis, B., Siritanakatkul, N., Jackson, B.F., Cochrane, J., Prescott, E. & Wonke, B. (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood, 91, 295-300.
25. Hoffbrand, A.V., Cohen, A. & Hershko, C. (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood, 102, 17-24.
26. Hoyes, K.P. & Porter, J.B. (1993) Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. British Journal of Haematology, 85, 393-400.
27. Hyman, C.B., Agness, C.L., Rodriguez-Funes, R. & Zednikova, M. (1985) Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia. Annals of New York Academy of Sciences, 445, 293-303.
28. Jensen, P.D., Jensen, F.T., Christensen, T., Eiskjaer, H., Baandrup, U. & Nielsen, J.L. (2003a) Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood, 101, 4632-4639.
29. Jensen, P.D., Jensen, F.T., Christensen, T., Nielsen, J.L. & Ellegaard, J. (2003b) Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood, 101, 91-96.
30. Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, P., Garozzo, G., Malizia, R., Magnano, C., Mangiagli, A., Quarta, G., Rizzo, M., D'Ascola, D.G., Rizzo, A. & Midiri, M. (2002) Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells, Molecules and Diseases, 28, 196-208.
31. Marcus, R.E., Davies, S.C., Bantock, H.M., Underwood, S.R., Walton, S. & Huehns, E.R. (1984) Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet, 1, 392.
32. Miskin, H., Yaniv, I., Berant, M., Hershko, C. & Tamary, H. (2003) Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European Journal of Haematology, 70, 398-403.
33. de Montalembert, M., Jan, D., Clairicia, M., Hannedouche, T., Sidi, D. & Girot, R. (1992) Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-a-Cath). Archives Francaises de Pediatrie, 49, 159-163.
34. Olivieri, N.F. & Brittenham, G.M. (1997) Iron-chelating therapy and the treatment of thalassemia. Blood, 89, 739-761.
35. Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St Louis, P., Freedman, M.H., McClelland, R.A. & Templeton, D.M. (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet, 336, 1275-1279.
36. Olivieri, N.F., Berriman, A.M., Tyler, B.J., Davis, S.A., Francombe, W.H. & Liu, P.P. (1992) Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine. American Journal of Hematology, 41, 61-63.
37. Olivieri, N.F., Nathan, D.G., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G. & Cohen, A.R. (1994a) Survival in medically treated patients with homozygous β-thalassemia. New England Journal of Medicine, 331, 574-578.
38. Olivieri, N.F., Beluzzo, N., Mucara, M., MacKenzie, C.C., Polsinelli, K., Koren, G., Liu, P.P. & Brittenham, G.N. (1994b) Evidence of reduction in hepatic, cardiac and pituitary iron stores in patients with thalassemia major during long-term therapy with the orally-active iron chelating agent L1. Blood, 84, 109a.
39. Olivieri, N.F., Brittenham, G.N. & Armstrong, S.A.M. (1995) First prospective randomized trials of the iron chelators deferiprone (L1) and deferoxamine. Blood, 86, 249a.
40. Piga, A., Gaglioti, C., Fogliacco, E. & Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica, 88, 489-496.
41. Porter, J.B., Jaswon, M.S., Huehns, E.R., East, C.A. & Hazell, J.W.P. (1989) Desferrioxamine ototoxicity: evaluation of risk factors in thalasaemic patients and guidelines for safe dosage. British Journal of Haematology, 73, 403-409.
42. Porter, J.B., Abeysinghe, R.D., Hoyes, K.P., Barra, C., Huehns, E.R., Brooks, P.N., Blackwell, M.P., Araneta, M., Brittenham, G. & Singh, S. (1993) Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3- hydroxypyrid-4-one, CP94, relates to different metabolism of the iron chelating site. British Journal of Haematology, 85, 159-168.
43. Porter, J.B., Singh, S., Hoyes, K.P., Epemolu, O., Abeysinghe, R.D. & Hider, R.C. (1994) Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. Advances in Experimental Medicine and Biology, 356, 361-370.
44. Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C. & Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 88, 705-713.
45. Vogel, M., Anderson, L.J., Holden, S., Deanfield, J.E., Pennell, D.J. & Walker, J.M. (2003) Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. European Heart Journal, 24, 113-119.
46. Wacker, P., Halperin, D.S., Balmer-Ruedin, D., Oberhansli, I. & Wyss, M. (1993) Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest, 103, 1276-1278.
47. Wolfe, L., Olivieri, N., Sallan, D., Colan, S., Rose, V., Propper, R., Freedman, M.H. & Nathan, D.G. (1985) Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine, 312, 1600-1603.
48. Zurlo, M.G., De Stefano, P., Borgna-Pignatti, C., Di Palma, A., Piga, A., Melevendi, C., Di Gregorio, F., Burattini, M.G. & Terzoli, S. (1989) Survival and causes of death in thalassaemia major. Lancet, 8653, 27-30.